Perspective—weight loss, obstructive sleep apnea therapy, or both for cardiometabolic risk in obesity-related obstructive sleep apnea?
Abstract
The emergence of potent and durable obesity pharmacotherapies has the potential to drastically alter the treatment landscape for comorbid obesity and obstructive sleep apnea. Recent clinical trials examining the impact of weight loss on obstructive sleep apnea have demonstrated marked improvements in both weight and obstructive sleep apnea severity, leading to the first Food and Drug Administration approval of a weight loss medication for obstructive sleep apnea. However, several questions remain unanswered regarding which trial and management strategies will best optimize real-world outcomes for patients with comorbid obesity and obstructive sleep apnea in an equitable manner.
Fields of Study & Subjects
Obstructive Sleep Apnea Research
Bariatric Surgery and Outcomes
Pharmacology and Obesity Treatment
Publication details
- Journal / source
- SLEEP
- Publisher
- Oxford University Press (OUP)
- Volume
- 49
- Issue
- 7
- Publication date
- 23 April 2026
- Language
- EN